UroCor Labs

Joint Commission Accreditation Survey

UroCor Publications

UroCor accesses its specimen repository, disease databases and range of technical expertise to publish peer-reviewed articles in several leading medical and scientific journals.

  1. CarMichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, and Epstein JI.  Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.  J Urol 153 (3Pt2): 1015-1019, 1995.
  2. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O’Dowd GJ, and Veltri RW.  An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies and prostate specific antigen level. J Urol  156: 1375-80, 1996.
  3. Veltri RW, Miller MC, Partin AW, Coffey DS, and Epstein JI.  Ability to predict biochemical progression using Gleason score and computer-generated quantitative nuclear grade derived from cancer cell nuclei.  Urology  48: 685-91, 1996.
  4. Hurst RE, Roy JB, Kim KW, Veltri RW, Marley GM, Patton KP, Schackelford DL, Stein P, and Parsons CL.  A deficit of chondroitin sulfate proteoglycans on bladder uroepithelium in interstitial cystitis.  Urology  48: 817-821, 1996.
  5. Marley GM, Miller MC, Kattan MW, Zhao G, Patton KP, Vessella RL, Wright Jr. GL, Schellhammer PF, and Veltri RW.  Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.  Urology  48(6A): 16-22, 1996.
  6. An G, Luo GZ, Veltri RW, and O'Hara SM. Sensitive, non-radioactive differential display method using chemiluminescent detection.  BioTechniques  20(3): 342-346, 1996.
  7. Ralph DA, Veltri RW, Horten B, and DaSilva M. Making strides in cancer detection, diagnosis. Advance/Laboratory  September : 48-53, 1996.
  8. Silberman MA, Partin AW, Veltri RW, and Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.  Cancer  79: 772-79, 1997.
  9. Slaton JW, Dinney CPN, Veltri RW, Miller MC, Leibert M, O’Dowd GJ, and Grossman HB.  DNA ploidy enhances the cytologic prediction of recurrent transitional cell carcinoma of the bladder.  J Urol  158(3): 806-811, 1997.
  10. O’Dowd GJ, Veltri RW, Orozco R, Miller MC, and Oesterling JE.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer.  J Urol  158(3): 687-698, 1997.
  11. Wojcik EM, Miller MC, Wright BC, Veltri RW. Comparative analysis of DNA content in polyoma virus infected urothelial cells, urothelial dysplasia and high grade transitional cell carcinoma.  Anal Quant Cytol  19(5): 430-436, 1997.
  12. Ralph DA and Veltri RW.  Prostate Cancer Progress.  Advance/Laboratory  April: 51-56, 1997.
  13. Veltri RW and Holzman D.  News article:  Algorithms vie for diagnostic role in prostate cancer.  JNCI  89(1): 1-4;15, 1997.
  14. Moreno JG, O’Hara SM, Long JP, Veltri RW, Ning X, Alexander AA, and Gomella LG.  Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR.  Urology 49(4): 515-520, 1997.
  15. Wojcik EM, Miller MC, O’Dowd GJ, and Veltri RW. Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade TCC.  Anal Quant Cytol Histol  20(1): 69-76, 1998.
  16. Orozco R, O’Dowd GJ, Kunnel B, Miller MC, and Veltri RW.  Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States.  Urology  51(2): 186-195, 1998.
  17. Veltri RW, O'Dowd GJ, Orozco R, Miller MC.  The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis.  Sem Urol Oncl  16(3): 106-117, 1998.
  18. Dinney CP, Babkowski RC, Antelo M, Perrotte P, Liebert M, Zhang HZ, Palmer J, Veltri RW, Katz RL, and Grossman HB. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.  J Urol  160(4): 1285-1290, 1998.
  19. An G, Cazares L, Luo G, Miller MC, Wright GL, and Veltri RW.  Differential expression of full length and a truncated Her-2/neu oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR.  Mol Urol  2(4): 305-310, Winter 1998.
  20. Veltri RW, Miller MC, Zhao G, Ng AY, Marley GM, Wright GL, Vessella RL, and Ralph DA.  Interleukin-8 (IL-8) serum levels in patients with benign prostatic hyperplasia and prostate cancer.  Urology  53(1): 139-147, 1999.
  21. Veltri RW and Miller MC.  Free/Total Ratios improve differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations.  Urology  53(4): 736-745, 1999.
  22. Pickens CL, Milliron AR, Fussner AL, Dversdall BC, Langenstroer P, Ferguson S, Fu X, Schmitz F, and Poole EC.  Abuse of guaifenesin containing medications generate an excess of a carboxylate salt of b-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolitie, and result in urolithiasis.  Urology  54(1): 23-27, 1999.
  23. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, and Partin AW.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.  Urology  54(5): 791-795, 1999.
  24. An G, Meka CS Reddy, Bright SP, Veltri RW. Human prostate transglutaminase (pTGase) gene: promoter cloning: tissue specific expression and down regulation in metastatic prostate cancer (CaP).  Urology  54(6): 1105-1111, 1999.
  25. Prescott J, Patel H, Tillman S, McHugh T, and Ralph DA. Cleavage of double stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in Clinical Specimens.  Electrophoresis  20: 1149-61, 1999.
  26. Vessella RL, Gomella LG, Moreno JG, and Veltri RW. Review of De La Taille, A et al. Molecular staging of prostate cancer: dream or reality.  Oncology  13(2): 194-209, 1999.
  27. Reckwitz T, Potter SR, Snow PB, Zhang Z, Veltri RW, and Partin AW.  Artificial neural networks in urology: Update 2000.  Prostate Cancer & Prostatic Diseases  2: 222-226, 1999.
  28. Ng A, Bales WD, and Veltri RW.  Phenylbutyrate induced apoptosis and differential expression of BCL-2, BAX, p53, and FAS in human Prostate Cancer Cell Lines.  Analytical and QuantitativeCytology and Histology22(1): 45-54, 2000.
  29. O’Dowd GJ, Miller MC, Orozco R, and Veltri RW. Analysis of repeat biopsy results within one year following a non-cancer diagnosis.  Urology 55: 553-559, 2000.
  30. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PBC, Stonebrook KA, and DeKernion JB.  Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.  J Urol  163(5): 1451-1456, 2000.
  31. Wojcik EM, Bridges VJ, Miller MC, O’Dowd GJ. Influence of season on the incidence of DNA hypodiploidy in urinary cytology.  Cytomerty (Comm. Clin. Cytometry)  42: 218-220, 2000.
  32. An G, Ng AY, Meka CSR, Lou G, Bright SP, Cazares L, Wright, Jr. GL, and Veltri RW.  Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers.  Cancer Res  60: 7014 - 7020, 2000.
  33. O’Dowd GJ, Veltri RW, Miller MC, and Strum SB.  The Gleason score: a significant biologic manifestation of prostate cancer aggressiveness on biopsy. PCRInsights  4(1): 1-5, 2001.
  34. Veltri RW, Miller MC, and An G. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.  Urology  57(4A): 164-170, 2001.
  35. Miller MC, O’Dowd GJ, Partin AW, and Veltri RW.  Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.  Urology 57(6): In Press, 2001.
  36. Prescott JL, Montie J, Pugh TW, McHugh T, and Veltri RW.  Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.  Cancer  91(10): In Press, 2001.
  37. Veltri RW, Partin AW, and Miller MC. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.  J Cell Biochem  In Press, 2001.
  38. Veltri RW, Miller MC, Partin AW, Poole E, and O’Dowd GJ.  Prediction of prostate cancer stage using quantitative biopsy pathology.  Cancer  In Press, 2001.